Entera Bio Scores FDA Feedback on Phase 3 After 161-Patient Phase 2 Bone Density Gains
ENTX•Entera Bio’s oral anabolic EB613 showed significant spine, hip and femoral neck bone density gains in a 161-patient Phase 2 trial and secured positive FDA feedback on a 750-patient Phase 3 design set to start late 2026. With an $80 million market cap, it trails Novo Nordisk’s $2.1 billion oral peptide deal.
1. Treatment Gap and Opportunity
Up to 87% of women with fragility fractures in some states receive no osteoporosis treatment, contributing to a global population of 200 million women living with the disease and underscoring a large market opportunity for new therapies.
2. EB613 Phase 2 Efficacy
EB613, the once-daily oral PTH(1-34) tablet, delivered significant bone density increases at spine, hip and femoral neck in a 161-patient placebo-controlled Phase 2 trial, meeting both primary and secondary endpoints with statistical significance.
3. FDA Phase 3 Protocol
Entera received positive feedback on a streamlined 750-patient registrational Phase 3 design focused on 12-month bone density endpoints, targeting trial initiation in late 2026 and top-line results by H2 2028.
4. Valuation vs Big Pharma Investments
At approximately $80 million market capitalization, Entera’s entire value is roughly 25 times less than Novo Nordisk’s $2.1 billion investment in oral-peptide technology alone, despite Entera’s platform advancing through human efficacy trials and multiple pipeline programs.
